Florida Cancer Specialists Expands Participation in Oncology Care Model
Fort Myers, Fla., November 21, 2019 — In June 2016, Florida Cancer Specialists & Research Institute (FCS) was selected to participate in the Oncology Care Model (OCM), a national innovative payment program of the Center for Medicare & Medicaid Innovation (CMMI), a division of the Centers for Medicaid & Medicare (CMS). Through this participation, FCS committed to providing high-quality enhanced services to Medicare beneficiaries, such as care coordination, navigation and national treatment guidelines, while reducing the cost of cancer care through payment arrangements that include financial and performance accountability.
Data compiled by CMMI demonstrated that FCS was able to successfully achieve savings in this program while continuing to deliver high-quality services to more than 16,000 participating patients. Based on this success, FCS is expanding its participation in the OCM by choosing to adopt an alternative “two-sided risk” model that would create additional savings for patients and, potentially, for the practice. In the new two-sided risk model, providers still share in savings, if spending is below the benchmark, as they do in the previous one-sided risk model; however, under the two-sided model, providers also are responsible for some of the loss if spending is above the benchmark.
FCS CEO Brad Prechtl, MBA, said, “Since joining the OCM in 2016, FCS has demonstrated a consistent history of positive performance over time, while outpacing the expected target predicted by CMMI. Consistent cost inflation has been significantly lower than Medicare’s predicted expectation for our increase in cost. Several key factors have contributed to our success and, based on our solid track record, I anticipate even greater achievements in the future.”
Sarah Cevallos, FCS chief revenue cycle officer, added, “FCS represents approximately 9% of all Medicare beneficiaries included in the OCM nationally. This large volume of patients will be a significant asset in ensuring we are able to monitor key areas, such as clinical trends, to provide proactive guidance to our team on patients more prone to hospitalizations or unnecessary emergency room visits. Models like the OCM have driven FCS to make substantial strides in our strategic focus on value-based programs that have allowed us to reinvest in our patients, payer partners and within our organization.”
FCS President & Managing Physician Dr. Lucio Gordan expressed optimism regarding the practice’s participation in the new two-sided model, saying, “We are confident that we will set a national benchmark for practices within the OCM because we have high physician engagement and alignment with our strategic priorities. At FCS, our guiding principle is to always put the patient first in everything we do. We are laser-focused on providing world-class cancer care while reducing the overall cost of that care for our patients.”
# # #
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, FCS is one of the largest medical oncology/hematology practices in the United States. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
*Prior to approval
For More Information, Contact:
Shelly Glenn, Chief Marketing & Sales Officer
Michelle Robey, Director of Marketing & Communications